Screener
Aquestive Therapeutics, Inc. AQST Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Aquestive Therapeutics, Inc.’s 10-Q, filed August 11, 2026. Open the filing →
- Filed
- Aug 11, 2026, 4:10 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001398733-26-000042
FAQ
- What is Aquestive Therapeutics, Inc.'s total liabilities?
- Aquestive Therapeutics, Inc. (AQST) reported total liabilities of $188.69M in Q2 2026.
- How has Aquestive Therapeutics, Inc.'s total liabilities changed year-over-year?
- Aquestive Therapeutics, Inc.'s total liabilities increased by 13.5% year-over-year, from $166.29M to $188.69M.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s total liabilities?
- Over 5 years (2020 to 2025), Aquestive Therapeutics, Inc.'s total liabilities has grown at a 11.7% compound annual growth rate (CAGR), from $111.38M to $194.09M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Aquestive Therapeutics, Inc.'s total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude